$CUE

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001645460 0001645460 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Ju

Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.

Cue Biopharma (Nasdaq: CUE) appointed Dominic Borie as Chief Medical Officer and Head of R&D. The company expects Phase 2 data readout for CUE-221 by end of Q3 2026 and plans a Phase 1 trial of CUE-401 by end of Q4 2026. Cue also disclosed a $50M private placement to fund clinical development.

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d123955dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of July 9, 2026, by and among Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), and each of the purchasers liste

Cue Biopharma (CUE) said it agreed to a private placement of 1,418,071 shares at $33.21 each, plus pre-funded warrants for up to 87,500 shares at $33.209 per warrant, for about $50 million gross proceeds. The deal is expected to close around July 13, 2026. Proceeds will fund clinical development and general corporate use.

Cue Biopharma (CUE) entered a definitive agreement for an approximately $50.0M gross private placement with accredited institutional investors. The financing is described as oversubscribed and includes issuance of 1.42M shares of common stock, according to the company.

Cue Biopharma (Nasdaq: CUE) announced a $50.0 million private placement. It will sell 1,418,071 common shares at $33.21 each and issue pre-funded warrants for up to 87,500 shares at $33.209 per warrant, with a $0.001 exercise price. Closing is expected around July 13, 2026. Proceeds will fund clinical development and general corporate purposes.

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

Cue Biopharma announced inducement equity awards to seven new employees, including newly appointed CEO Shao-Lee Lin, M.D., Ph.D. Dr. Lin received a non-statutory option for 655,074 shares and 327,537 restricted stock units, with the option vesting over four years and RSUs fully vested upon grant. Six other employees also received significant stock options and RSUs, with all awards granted under the company's 2026 Inducement Stock Incentive Plan at an exercise price of $30.42 per share.